No closing price yetNo closing price yet, so we show no figure rather than a guess. Shares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily.CIK 1001233The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 2 sells
$107.4K sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Sangamo Therapeutics, Inc's latest quarterly report, compared with the one before.
We have not read a recent 10-Q for this company yet.
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Sangamo Therapeutics, Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
H-1B labor applications at Sangamo Therapeutics, Inc
0 certified in 12 mo
Labor condition applications decided by the Department of Labor, matched to Sangamo Therapeutics, Inc by employer name. An application is not a hire.
Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —The wage the employer offered, as filed, with its unit. The yearly figure restates it per year (hourly x 2,080, weekly x 52, every two weeks x 26, monthly x 12) from the low end of the offered range. It is not what the worker was paid.
H-1B labor applications decided at Sangamo Therapeutics, Inc by quarter
We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q2 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
6
0.1% of shares · 1 added
Insider trades
2 in 12 mo
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
6 funds report SGMOQ. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 0.1% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 533,408 reported shares by 414.29M shares, from the cover page of the company’s filing as of May 11, 2026.
6 funds hold the stock.
Q1 202523%
Q2 202524%
Q3 202519%
Q4 202519%
Q1 202625%
Q2 20260.1%
Reports for the quarter ending Sep 30, 2026 are still coming in (2 positions so far, against 8 the quarter before), so we compare the two complete quarters before it.
Q2 2026. 2 new, 1 added to, 0 trimmed, 109 exited since Q1 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds SGMOQ, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Sangamo Therapeutics, Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
98
—
30.58M
$238.9M
Q3 2013
110
+12
39.20M
$411.2M
Q4 2013
115
+5
46.27M
$642.7M
Q1 2014
146
+31
48.28M
$872.4M
Q2 2014
155
+9
49.75M
$759.5M
Q3 2014
157
+2
48.83M
$526.7M
Q4 2014
158
+1
49.19M
$747.7M
Q1 2015
171
+13
52.70M
$826.0M
Q2 2015
155
-16
50.58M
$560.8M
Q3 2015
141
-14
52.67M
$297.1M
Q4 2015
141
0
49.10M
$448.3M
Q1 2016
142
+1
48.69M
$292.4M
Q2 2016
136
-6
46.51M
$269.3M
Q3 2016
122
-14
42.60M
$197.2M
Q4 2016
126
+4
41.86M
$127.8M
Q1 2017
117
-9
42.20M
$219.3M
Q2 2017
143
+26
53.04M
$466.8M
Q3 2017
148
+5
54.85M
$822.7M
Q4 2017
170
+22
55.84M
$955.5M
Q1 2018
208
+38
57.20M
$1.1B
Q2 2018
210
+2
65.47M
$929.7M
Q3 2018
217
+7
67.25M
$1.1B
Q4 2018
196
-21
65.77M
$754.7M
Q1 2019
187
-9
65.97M
$630.2M
Q2 2019
185
-2
81.93M
$883.7M
Q3 2019
183
-2
82.73M
$749.6M
Q4 2019
193
+10
80.07M
$670.1M
Q1 2020
190
-3
74.56M
$475.9M
Q2 2020
205
+15
77.13M
$690.9M
Q3 2020
210
+5
81.63M
$772.3M
Q4 2020
222
+12
78.92M
$1.2B
Q1 2021
202
-20
79.44M
$994.8M
Q2 2021
196
-6
76.21M
$912.1M
Q3 2021
192
-4
75.28M
$679.3M
Q4 2021
192
0
77.35M
$580.3M
Q1 2022
193
+1
79.03M
$460.0M
Q2 2022
187
-6
89.68M
$371.1M
Q3 2022
196
+9
97.72M
$479.1M
Q4 2022
182
-14
103.97M
$326.1M
Q1 2023
179
-3
113.53M
$199.7M
Q2 2023
152
-27
105.93M
$137.4M
Q3 2023
134
-18
103.49M
$62.0M
Q4 2023
130
-4
89.25M
$48.4M
Q1 2024
131
+1
103.38M
$69.8M
Q2 2024
129
-2
86.90M
$31.1M
Q3 2024
103
-26
56.20M
$48.7M
Q4 2024
128
+25
61.60M
$62.9M
Q1 2025
123
-5
52.56M
$34.5M
Q2 2025
114
-9
73.75M
$39.9M
Q3 2025
113
-1
62.61M
$42.1M
Q4 2025
106
-7
62.27M
$26.2M
Q1 2026
113
+7
105.39M
$26.0M
Q2 2026
6
-107
533,408
$29.0K
Q3 2026
2
-4
1,501
$0
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (800677106). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.